Results 221 to 230 of about 274,980 (287)

Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort. [PDF]

open access: yesPituitary
Yuen KCJ   +10 more
europepmc   +1 more source

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies. [PDF]

open access: yesJ Cachexia Sarcopenia Muscle
Breen DM   +14 more
europepmc   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

open access: yesInternational Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier   +19 more
wiley   +1 more source

The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition

open access: yesInternational Journal of Cancer, EarlyView.
Although immune checkpoint inhibitors (ICI) have transformed metastatic melanoma treatment, thromboembolic events (TEEs) remain a serious complication. Moreover, existing risk assessment models were developed prior to ICI use and lack clinical validation.
Tim Zell   +12 more
wiley   +1 more source

Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study. [PDF]

open access: yesClin Cosmet Investig Dermatol
Aggarwal R   +9 more
europepmc   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

open access: yesInternational Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner   +16 more
wiley   +1 more source

The Relevance of Curative‐Intent Metastasectomy in Colorectal Cancer Patients: Real‐World Insights From a Certified Comprehensive Cancer Center in Germany

open access: yesInternational Journal of Cancer, EarlyView.
Patients with metastatic colorectal cancer who are ineligible for upfront metastasectomy may still become candidates for secondary metastasectomy with curative intent following response to primary chemotherapy. However, most studies dichotomize metastatic colorectal cancer into resectable and unresectable disease.
Julian W. Holch   +18 more
wiley   +1 more source

Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries. [PDF]

open access: yesBlood Adv
Andemariam B   +11 more
europepmc   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

open access: yesInternational Journal of Cancer, EarlyView.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel   +26 more
wiley   +1 more source

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results). [PDF]

open access: yesVaccines (Basel)
Dadhe R   +17 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy